ARB-1467 / Arbutus - LARVOL DELTA

Hot News: Hepatitis B Gene Therapy Coming to Age. (PubMed, AIDS Rev) - "...Third, the specificity against HBV is higher than for other experimental agents, as immune modulators that enhance innate immunity, such as TLR agonists (i.e., GS-9620) or checkpoint inhibitors (i.e., nivolumab). Fourth, significant declines in serum hepatitis B surface antigen (HBsAg) are demonstrated during gene therapy, which have never been seen using the most potent polymerase inhibitors (i.e., tenofovir or entecavir)...Exp Op Biol Ther, in press), including ARB-1467 and AB-729 (Arbutus), ARO-HBV (Arrowhead), ALN-HBV (Alnylam), and IONIS-HBVRx (Ionis)...In a pilot study with intravenous REP-2139, investigators from Replicor demonstrated strong reductions in HBV-DNA along with significant drops in HBsAg and seroconversion in some patients...EASL, Paris 2018; abstract FRI-343). An improved NAP, named REP-2165 and subcutaneous administration are currently being tested."

Journal • PD(L)-1 Biomarker • Biosimilar • Gene Therapies • Hepatitis C Virus • Immune Modulation • Immunology • Inflammation

Preclinical profile of AB-423, an inhibitor of Hepatitis B virus pgRNA encapsidation. (PubMed, Antimicrob Agents Chemother) - "A 7-dayadministration of AB-423 in a hydrodynamic injection mouse model of HBV model resulted in a dose-dependent reduction in serum HBV DNA levels and combination with ETV or ARB-1467 resulted in a trend towards greater antiviral activity than either agent alone consistent with the results of thecombination studies. The overall preclinical profile of AB-423 supports further evaluation for safety, pharmacokinetics and antiviral activity in CHB patients."

Journal • Preclinical